EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review

Jinfang Song, Xia Li, Jiang Ni

Kidney and Blood Pressure Research · 2023

DOI: 10.1159/000534174 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney and Blood Pressure Research, 2023. Verfasst von Jinfang Song und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, China, songjinfang1987@126.com. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetic Nephropathies, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering drug, have been well proved in several clinical studies for their glucose-lowering and nephroprotective effects, and the nephroprotective effects include both indirect effects of metabolic improvement and direct effects, independent of glucose-lowering effects. Summary: In patients with diabetic kidney disease (DKD), several studies have demonstrated the potential nephroprotective mechanisms of SGLT2 inhibitors, and evidence of nephroprotective mechanisms in the non-DKD population is accumulating. Although the nephroprotective mechanism of SGLT2 inhibitors has not been fully elucidated, several laboratory studies have illustrated the mechanism underlying the effects of SGLT2 inhibitors at various aspects. Key Messages: The purpose of this article is to review the mechanism of nephroprotective effect of SGLT2 inhibitors and to look forward to promising research in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetic NephropathiesRenal Insufficiency, ChronicDiabetes Mellitus, Type 2HumansGlucoseSodiumKidneyHypoglycemic Agents

Stichwörter der Autor:innen

Chronic kidney diseaseDiabetic kidney diseaseNon-diabetic kidney diseaseSGLT2 inhibitor

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucoseSodiumHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, China, songjinfang1987@126.com.
  • Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China, songjinfang1987@126.com.
  • Department of Clinical Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, China.
  • Wuxi School of Medicine, Jiangnan University, Jiangsu Province, Wuxi, China.

Zitieren

APA

Song, J., Li, X., & Ni, J. (2023). A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review. Kidney and Blood Pressure Research. https://doi.org/10.1159/000534174

Vancouver

Song J, Li X, Ni J. A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review. Kidney and Blood Pressure Research. 2023. doi:10.1159/000534174

BibTeX
@article{Song2023,
  author = {Song, Jinfang and Li, Xia and Ni, Jiang},
  title = {A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review},
  journal = {Kidney and Blood Pressure Research},
  year = {2023},
  doi = {10.1159/000534174}
}
Kostenlos starten →